What is the mechanism behind Filitra 40 Mg effect on blood flow?
Filitra 40 mg is a medication used to treat erectile dysfunction (ED) in men. It contains vardenafil hydrochloride, which is a phosphodiesterase type 5 (PDE5) inhibitor.
The mechanism of action of Filitra 40 mg involves its ability to inhibit the enzyme phosphodiesterase type 5 (PDE5) in the smooth muscle cells of the blood vessels in the penis. When a man is sexually stimulated, nitric oxide is released in the erectile tissue of the penis. Nitric oxide then activates an enzyme called guanylate cyclase, which results in increased levels of cyclic guanosine monophosphate (cGMP).
cGMP is a signaling molecule that relaxes smooth muscle cells in the blood vessels, leading to vasodilation (widening of the blood vessels) and increased blood flow to the erectile tissue of the penis. This increased blood flow helps to facilitate an erection by allowing the penis to become engorged with blood, resulting in rigidity and firmness.
PDE5 is an enzyme that breaks down cGMP, thereby reducing its levels in the blood vessels and diminishing its vasodilatory effects. By inhibiting PDE5, Filitra 40 mg helps to prolong the effects of cGMP, allowing for increased blood flow to the penis and improved erectile function.
It's important to note that Filitra 40 mg should be taken as directed by a healthcare provider and is effective only when a man is sexually stimulated. Additionally, Filitra 40 mg should not be taken with certain medications or in individuals with certain medical conditions without consulting a healthcare provider, as it may cause potentially serious interactions or adverse effects.